Atossa Therapeutics (NASDAQ: ATOS) is a clinical-stage biopharmaceutical company developing drug candidates centered on (Z)-endoxifen, a selective estrogen receptor modulator. The company generates no product revenue; operations are funded entirely through equity issuances and, as needed, short-term borrowings. As of the fiscal year ended December 31, 2025, Atossa reported a net loss of $34.8 million and an accumulated deficit of $246.6 million, with no approved commercial products. The company is pursuing (Z)-endoxifen across multiple indications, including breast conditions, McCune-Albright Syndrome with precocious puberty, and Duchenne and Becker muscular dystrophy carriers. Atossa has disclosed going-concern risk, noting that additional capital will be required to fund operations beyond the next 12 months from the filing date of March 25, 2026. The company is incorporated in Delaware and listed on the Nasdaq Capital Market.

Revenue model

No product revenue as of FY2025. Operations are financed through at-the-market equity offerings, including an ATM agreement with Rodman & Renshaw LLC dated February 20, 2026, and potential short-term borrowings. The company has not established a recurring revenue source.

Products and services

(Z)-endoxifen oral formulation in clinical development for breast-related indications, McCune-Albright Syndrome with precocious puberty, and symptomatic female Duchenne and Becker muscular dystrophy carriers. No products are approved or commercialized as of the filing date.

Customers and end markets

No commercial customers as of FY2025. Target end markets include oncology and rare disease, specifically patients with hormone-sensitive breast conditions, young girls with precocious puberty caused by McCune-Albright Syndrome, and female carriers of Duchenne and Becker muscular dystrophy experiencing skeletal-muscle symptoms or dilated cardiomyopathy.

Value-chain role

Drug developer relying on third-party contract research organizations and clinical service providers for trial execution. Internal responsibilities include clinical oversight, regulatory strategy, and IP management. No manufacturing or commercial distribution infrastructure disclosed.

Geographic exposure

Primary regulatory focus on the United States (FDA). Operations subject to EU, UK GDPR, and EU member-state pharmaceutical advertising rules, indicating at least anticipated clinical or regulatory activity in Europe. No geographic revenue breakdown available given pre-revenue status.

Source: SEC 10-K, filed 2026-03-25

Industry: Pharmaceutical Preparations Peers: Alzamend Neuro Inc Annovis Bio Inc Lunai Bioworks Inc INFINITY PHARMACEUTICALS, INC. Puma Biotechnology Inc Inozyme Pharma, Inc. MediciNova Inc Tourmaline Bio, Inc.